-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
On March 29, CDE's official website showed that Jiahe Bio's application for clinical trials of EGFR/c-Met/c-Met trispecific antibodies in China was accepted by the State Food and Drug Administration
GB263T is the world's first EGFR/c-Met/c-Met trispecific antibody, targeting EGFR and two different c-Met epitopes
In vitro studies and in vivo animal models have demonstrated its antitumor activity
The antitumor activity of GB263T was evaluated in multiple tumor models including Ba/F3 EGFR-D770del-insGY, Ba/F3 EGFR-D770-N771-insSVD, Ba/F3
EGFR-ex19del/T790M/C797S, HCC827/ER1, LU2503 PDX model (c-Met exon 14 skipping mutation), etc.
In the cynomolgus monkey toxicology study, even in the high-dose group, no significant adverse reactions were observed after 4 weeks of administration